We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $6.57, which surpassed the Zacks Consensus Estimate by 2.18%. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 2.78%.
Q1 Estimates for TMO
The Zacks Consensus Estimate for revenues is pegged at $10.83 billion, indicating an increase of 4.5% from the year-ago reported figure.
The same for the company’s EPS implies a 1.2% year-over-year rise to $5.21.
Estimate Revision Trend Ahead of TMO’s Q1 Earnings
Estimates for Thermo Fisher’s Q1 earnings have remained constant at $5.21 in the past 30 days.
Here’s a brief review of the company’s performance leading up to the announcement.
Factors Likely to Influence TMO’s Q1 Results
Life Sciences Solutions
Similar to recent quarters, the segment’s revenues are likely to have been driven by the Bioproduction business. Within this, Thermo Fisher expanded the single-use portfolio with the launch of the Thermo Scientific 5-liter DynaDrive single-use bioreactor, which might have improved workflow efficiencies for the pharma and biotech customers. Other recent high-impact innovations include two chemically-defined formulations within the Gibco Bacto CD portfolio and the Gibco Efficient-Pro Medium (+) Insulin for insulin-dependent CHO cell lines. The company also expanded its bioprocessing capabilities across Asia, an emerging global hub for biopharmaceutical innovation.
Further, the addition of the Filtration and Separation business from Solventum has further strengthened the Bioproduction offerings with advanced filtration technologies and industrial filtration and membrane solutions. We expect all these developments to have positively boosted revenues in the first quarter of 2026.
Per the Zacks Consensus Estimate, the Life Sciences Solutions revenues are expected to increase 7.9% year over year.
Analytical Instruments
In the first quarter, the segment’s revenues might have been aided by robust growth in the chromatography and mass spectrometry business. On the innovation front, Thermo Fisher introduced the Scios 3 and Talos 12 electron microscopes and an enterprise-ready compliance-focused software platform called Chromeleon 7.4 that unifies chromatography and mass spectrometry workflows.
Thermo Fisher Scientific Inc. Price and EPS Surprise
The company also launched Orbitrap Exploris EFOX Mass Detector, aimed at detecting per- and polyfluoroalkyl substances, pesticides and other pollutants in food and water quality testing.
In addition, TMO and NVIDIA have teamed up to leverage the NVIDIA Artificial Intelligence platform and Thermo Fisher Scientific solutions to progressively increase the automation, accuracy and speed of laboratories. Combined, these developments are likely to have supported the quarter’s revenue performance.
Per the Zacks Consensus Estimates, revenues in this segment are projected to increase 1.3% year over year.
Specialty Diagnostics
The segment’s revenues in the first quarter are likely to have been led by the clinical diagnostics, transplant diagnostics and immunodiagnostics businesses. Recent launches include the Thermo Scientific Brilliance Candida 2 Agar and Spectra Candida Agar, new color-based (chromogenic) culture media to help quickly detect and differentiate clinically important Candida species. The company also introduced a new laboratory-developed test to help transplant patients receive the right dose of critical anti-rejection medication faster.
Further, Thermo Fisher’s Ion Torrent Oncomine Dx Target Test has been FDA-approved as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with Bayer’s HYRNUO (sevabertinib). The test is already widely accessible thanks to its broad reimbursement coverage. We expect Thermo Fisher’s top-line in the first quarter of 2026 to have been positively impacted by these factors.
The Zacks Consensus Estimate projects the segment’s revenues to grow 1.2% year over year.
Laboratory Products and Biopharma Services
The segment’s organic revenues are expected to have benefited from the strength across the research and safety market channel and the pharma services and clinical research businesses. Besides, the 2023 acquisition of CorEvitas has added highly complementary real-world evidence solutions to the segment’s portfolio, enhancing decision-making as well as the time and cost of drug development.
In February, the PPD clinical research business announced a strategic data collaboration with Datavant, under which its data linkage technology will be combined with Thermo Fisher’s deep clinical research expertise and infrastructure to bring richer, more connected patient data into the research process.
Per the Zacks Consensus Estimate, revenues in this segment are projected to increase 2% year over year in the first quarter of 2026.
What Our Model Unveils for TMO
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is exactly the case here, as you can see below.
Earnings ESP: Thermo Fisher has an Earnings ESP of +1.23%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
In the trailing four quarters, AGEN delivered an average surprise of 31.42%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 289.3% from the year-ago quarter’s figure.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +2.38% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.93%. The Zacks Consensus Estimate for the company’s first-quarter EPS calls for an increase of 17.8% from the year-ago quarter’s figure.
OnKure Therapeutics (OKUR - Free Report) has an Earnings ESP of +10.74% and a Zacks Rank #2. The company is expected to release first-quarter 2026 results soon.
OKUR’s earnings beat estimates in each of the trailing four quarters, the average surprise being 10.06%. The Zacks Consensus Estimate for the company’s first-quarter loss per share is pegged at up 31.9% from the year-ago reported figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Key Takeaways
Thermo Fisher Scientific (TMO - Free Report) is set to release first-quarter 2026 results on April 23, before the market opens.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $6.57, which surpassed the Zacks Consensus Estimate by 2.18%. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 2.78%.
Q1 Estimates for TMO
The Zacks Consensus Estimate for revenues is pegged at $10.83 billion, indicating an increase of 4.5% from the year-ago reported figure.
The same for the company’s EPS implies a 1.2% year-over-year rise to $5.21.
Estimate Revision Trend Ahead of TMO’s Q1 Earnings
Estimates for Thermo Fisher’s Q1 earnings have remained constant at $5.21 in the past 30 days.
Here’s a brief review of the company’s performance leading up to the announcement.
Factors Likely to Influence TMO’s Q1 Results
Life Sciences Solutions
Similar to recent quarters, the segment’s revenues are likely to have been driven by the Bioproduction business. Within this, Thermo Fisher expanded the single-use portfolio with the launch of the Thermo Scientific 5-liter DynaDrive single-use bioreactor, which might have improved workflow efficiencies for the pharma and biotech customers. Other recent high-impact innovations include two chemically-defined formulations within the Gibco Bacto CD portfolio and the Gibco Efficient-Pro Medium (+) Insulin for insulin-dependent CHO cell lines. The company also expanded its bioprocessing capabilities across Asia, an emerging global hub for biopharmaceutical innovation.
Further, the addition of the Filtration and Separation business from Solventum has further strengthened the Bioproduction offerings with advanced filtration technologies and industrial filtration and membrane solutions. We expect all these developments to have positively boosted revenues in the first quarter of 2026.
Per the Zacks Consensus Estimate, the Life Sciences Solutions revenues are expected to increase 7.9% year over year.
Analytical Instruments
In the first quarter, the segment’s revenues might have been aided by robust growth in the chromatography and mass spectrometry business. On the innovation front, Thermo Fisher introduced the Scios 3 and Talos 12 electron microscopes and an enterprise-ready compliance-focused software platform called Chromeleon 7.4 that unifies chromatography and mass spectrometry workflows.
Thermo Fisher Scientific Inc. Price and EPS Surprise
Thermo Fisher Scientific Inc. price-eps-surprise | Thermo Fisher Scientific Inc. Quote
The company also launched Orbitrap Exploris EFOX Mass Detector, aimed at detecting per- and polyfluoroalkyl substances, pesticides and other pollutants in food and water quality testing.
In addition, TMO and NVIDIA have teamed up to leverage the NVIDIA Artificial Intelligence platform and Thermo Fisher Scientific solutions to progressively increase the automation, accuracy and speed of laboratories. Combined, these developments are likely to have supported the quarter’s revenue performance.
Per the Zacks Consensus Estimates, revenues in this segment are projected to increase 1.3% year over year.
Specialty Diagnostics
The segment’s revenues in the first quarter are likely to have been led by the clinical diagnostics, transplant diagnostics and immunodiagnostics businesses. Recent launches include the Thermo Scientific Brilliance Candida 2 Agar and Spectra Candida Agar, new color-based (chromogenic) culture media to help quickly detect and differentiate clinically important Candida species. The company also introduced a new laboratory-developed test to help transplant patients receive the right dose of critical anti-rejection medication faster.
Further, Thermo Fisher’s Ion Torrent Oncomine Dx Target Test has been FDA-approved as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with Bayer’s HYRNUO (sevabertinib). The test is already widely accessible thanks to its broad reimbursement coverage. We expect Thermo Fisher’s top-line in the first quarter of 2026 to have been positively impacted by these factors.
The Zacks Consensus Estimate projects the segment’s revenues to grow 1.2% year over year.
Laboratory Products and Biopharma Services
The segment’s organic revenues are expected to have benefited from the strength across the research and safety market channel and the pharma services and clinical research businesses. Besides, the 2023 acquisition of CorEvitas has added highly complementary real-world evidence solutions to the segment’s portfolio, enhancing decision-making as well as the time and cost of drug development.
In February, the PPD clinical research business announced a strategic data collaboration with Datavant, under which its data linkage technology will be combined with Thermo Fisher’s deep clinical research expertise and infrastructure to bring richer, more connected patient data into the research process.
Per the Zacks Consensus Estimate, revenues in this segment are projected to increase 2% year over year in the first quarter of 2026.
What Our Model Unveils for TMO
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is exactly the case here, as you can see below.
Earnings ESP: Thermo Fisher has an Earnings ESP of +1.23%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Other Top MedTech Picks
Here are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
In the trailing four quarters, AGEN delivered an average surprise of 31.42%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 289.3% from the year-ago quarter’s figure.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +2.38% and a Zacks Rank #1. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.93%. The Zacks Consensus Estimate for the company’s first-quarter EPS calls for an increase of 17.8% from the year-ago quarter’s figure.
OnKure Therapeutics (OKUR - Free Report) has an Earnings ESP of +10.74% and a Zacks Rank #2. The company is expected to release first-quarter 2026 results soon.
OKUR’s earnings beat estimates in each of the trailing four quarters, the average surprise being 10.06%. The Zacks Consensus Estimate for the company’s first-quarter loss per share is pegged at up 31.9% from the year-ago reported figure.